-+ 0.00%
-+ 0.00%
-+ 0.00%

Antengene FY26 H1 returns to profit at RMB 216.35 million; revenue more than doubled to RMB 513.08 million

PUBT·08/21/2026 10:27:24
Listen to the news
Antengene FY26 H1 returns to profit at RMB 216.35 million; revenue more than doubled to RMB 513.08 million
  • Antengene posted IFRS revenue of RMB 513.08 million, up RMB 459.9 million, for the six months ended June 30, 2026.
  • IFRS profit attributable to owners swung to RMB 216.35 million; basic earnings per share turned positive at RMB 0.34.
  • R&D costs rose to RMB 122.92 million; selling and distribution expenses edged down to RMB 35.25 million.
  • Revenue included RMB 457.86 million of licensing and collaboration revenue tied to ATG-201 and ATG-106 out-licensing arrangements.
  • Business updates included an ATG-201 global license with UCB, ATG-106 licensing and an additional option deal with K2 Therapeutics.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12294388), on August 21, 2026, and is solely responsible for the information contained therein.